Page last updated: 2024-10-20

phosphorylethanolamine and Carcinoma, Hepatocellular

phosphorylethanolamine has been researched along with Carcinoma, Hepatocellular in 1 studies

phosphorylethanolamine: RN given refers to parent cpd; structure
O-phosphoethanolamine : The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.

Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Luna, ACL1
Saraiva, GKV1
Chierice, GO1
Hesse, H1
Maria, DA1

Other Studies

1 other study available for phosphorylethanolamine and Carcinoma, Hepatocellular

ArticleYear
Antiproliferative and proapoptotic effects of DODAC/synthetic phosphoethanolamine on hepatocellular carcinoma cells.
    BMC pharmacology & toxicology, 2018, 07-11, Volume: 19, Issue:1

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prolif

2018